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vestigated the effects of exogenous VIP and PACAP peptides 
in isolated carotid arteries of 2- and 15-month-old wild-type 
(WT) and PACAP-KO mice. All peptides induced relaxation in 
the arteries of young WT mice, whereas in young PACAP-KO 
mice PACAP1-27 and VIP, but not PACAP1-38, induced relax-
ation. Unlike VIP, PACAP-induced vasomotor responses were 
reduced in aging WT mice. However, in the arteries of aging 
PACAP-KO mice, PACAP1-27- and VIP-induced responses 
were reduced, but PACAP1-38 showed a greater vasomotor 
response compared to that of young PACAP-KO animals. 
There were no significant differences between the vasomo-
tor responses of aging WT and PACAP-KO mice. Our data 
suggest that, in the absence of PACAP both in young and old 
ages, the vascular response is mediated through backup 
mechanisms, most likely VIP, maintaining proper vascular re-
laxation in aging-induced PACAP insufficiency. 
 © 2017 S. Karger AG, Basel 
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 Abstract 
 Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 
and 1-27) and vasoactive intestinal peptide (VIP) are related 
neuropeptides of the secretin/glucagon family. Overlapping 
signaling through G-protein-coupled receptors mediates 
their vasomotor activity. We previously showed that PACAP 
deficiency (PACAP-KO) shifts the mechanisms of vascular 
response and maintains arterial relaxation through the VIP 
backup mechanism and (mainly) its VPAC1R, but their age-
dependent modulation is still unknown. We hypothesized 
that backup mechanisms exist, which maintain the vasomo-
tor activity of these peptides also in older age. Thus, we in-
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 Introduction 
 Pituitary adenylate cyclase-activating peptide (PA-
CAP) is a neuropeptide with a diverse array of biological 
functions. Among others, it affects hormone release, in-
fluences motility and growth, and it exerts protective ef-
fects in various cell types in the nervous system and pe-
ripheral organs  [1] . PACAP occurs in 2 biologically ac-
tive forms, PACAP1-38 (dominant) and PACAP1-27. 
Due to the high structural similarity between PACAP 
and vasoactive intestinal peptide (VIP), PACAP is clas-
sified as a member of the VIP-secretin-glucagon super-
family. Structurally, PACAP1-27 emerges from PA-
CAP1-38 by cleavage (which has the same amino acid 
order), and PACAP1-27 shares 68% sequence similarity 
with VIP  [1, 2] . PACAP exerts its effects through G-pro-
tein-coupled receptors, namely through the PACAP-
specific PAC1 receptor and through the VPAC1/VPAC2 
receptors, which transmit the effects of both PACAP and 
VIP  [1, 2] . In the vasculature, these receptors are located 
mainly in the smooth muscle cells of arteries and arteri-
oles  [1, 3] . 
 PACAP, like VIP, is a potent vasorelaxant peptide  [4, 
5] , and it causes a decrease in local and systemic blood 
pressure when given systemically  [4] . For example, infu-
sion of PACAP1-38, PACAP1-27, or VIP (0.25–25 pmol/
kg) in dog femoral arteries induces a concentration-de-
pendent increase in blood flow  [6] . The vasodilator activ-
ity of PACAP has also been recorded in vitro in vessels of 
various organs of mice  [7, 8] , rats  [9–11] , rabbits  [12] , 
pigs  [5] , and humans  [13] .
 The endogenous role of PACAP has been studied us-
ing PACAP-deficient (PACAP-KO) mice. PACAP-KO 
mice display several abnormalities, including alterations 
in locomotion, behavior, and changes in biochemical and 
metabolic parameters, resulting in several pathological 
features, in addition to higher mortality  [1, 14, 15] . The 
cardiovascular system is also affected by PACAP defi-
ciency, indicated by the decreased dilatator ability of ar-
teries  [8] , reduced cardiac function, increased fibrosis, 
and myocardial degenerative changes  [14] . Moreover, we 
have recently observed increased arterial relaxations to 
PACAP1-27 and VIP in PACAP-KO mice, and reduced 
vasomotor response to PACAP1-38  [7] .
 It has been shown that aging greatly affects the vaso-
motor function of vessels  [7] . In our recent study on rats, 
we have observed that relaxations induced by PACAP1-38 
were reduced in the arteries of older rats  [11] . Studies 
have also shown an age-related reduction of PACAP lev-
els in cerebral microvessels  [16, 17] . In addition, Banki et 
al.  [17] reported that reduced levels of PACAP lead to 
impaired angiogenic capacity of the cerebral microvascu-
lature in older age. The link between age-related neu-
rodegenerative diseases and PACAP has also been ad-
dressed  [1, 18] . Thus, it would be important to elucidate 
whether aging modulates PACAP- and VIP-mediated va-
somotor responses of peripheral arteries.
 We hypothesized that the vasomotor responses to PA-
CAP isoforms and VIP are substantially modulated by 
aging, both in PACAP-wild-type (WT) and PACAP-KO 
mice. Thus, in the present study, we aimed to investigate 
the relaxations of carotid arteries of young and aging PA-
CAP-WT and PACAP-KO mice in response to exoge-
nous PACAP1-38, PACAP1-27, and VIP.
 Methods 
 Animals 
 Two- and 15-month-old male PACAP-KO mice on a CD-1 
background and their WT littermates were used (total  n = 28; 
17 aged 2 months, 11 aged 15 months)  [15] . The mice weighed WT: 
2 months 42.73 ± 1.77 g, 15 months 41.5 ± 1.03 g; KO: 2 months 
36.8 ± 0.89 g, 15 months: 35.3 ± 0.49 g at the time of experiment. 
Animal breeding, housing, and experimental procedures were per-
formed according to ethical guidelines (University of Pecs, ethical 
permission No.: BA02/2000-15024/2011).
 Surgery 
 Common carotid arteries were isolated using a surgical micro-
scope (Olympus SZX7; Olympus Inc., Tokyo, Japan) under ke-
tamine/xylazine anesthesia induced by intraperitoneal adminis-
tration (ketamine: Gedeon Richter PLC., Budapest, Hungary; xy-
lazine: Eurovet Animal Health B.V., Bladel, The Netherlands). The 
anesthetics were given in 81.7 and 9.3 mg/kg doses, respectively. 
The proximal and distal ends of the isolated vessel segments were 
ligated; the vessel was excised between the ligations, and then 
transferred to refrigerated Krebs solution. Carotid arteries from 
both left and right sides were isolated, then the animals were killed 
with an intraperitoneal injection of pentobarbital (100 mg/kg; 
Ceva Sante Animale, Libourna, France).
 Measurement of Isometric Force of Isolated Carotid Arteries 
 Preparation and measurement of the isometric force of isolated 
carotid arteries were performed according to Mulvany and Hal-
pern  [19] and our previous experiments  [11] . After their removal, 
the vessel segments were quickly transferred into cold oxygenated 
physiological Krebs solution (mixture of 95% O 2 /5% CO 2 ; Linde, 
Repcelak, Hungary; NaCl: 119 m M , KCl: 4.7 m M , KH 2 PO 4 : 1.2 m M , 
NaHCO 3 : 25 m M , Mg 2 SO 4 : 1.2 m M , CaCl 2 × 2H 2 O: 1.6 m M , EDTA: 
0.026 m M , glucose: 11.1 m M ). NaCl and KCl were obtained from 
VWR International (Radnor, PA, USA). All other chemicals and 
drugs were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
unless specified otherwise. Two-millimeter-long rings were dis-
sected from the arteries. Each ring was positioned between 2 tung-
sten wires in the chamber (the diameter of the wire was 0.04 mm) 
in a 5-mL Krebs bath solution. The bath solution was continu-
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ously oxygenated with a gas mixture of 95% O 2 and 5% CO 2 and 
kept at 36.9 ± 0.1  °  C. 
 Isometric contraction forces were measured with a 4-chamber 
system, a DMT 610M Wire Myograph (Danish Myo Technology, 
Aarhus, Denmark). LabChart 8 (ADInstruments, Dunedin, New 
Zealand) and Myodaq 2.01 (Danish Myo Technology) software 
were used for data acquisition and display, according to previous 
descriptions  [11] . Vessels were allowed to stabilize for 60 min after 
normalization, then 60 m M KCl was administered for establishing 
a tone  [11, 20] . Once the vessel reached the plateau phase, the cho-
sen drug was tested.
 Pharmacological Agents Used in the Study 
 The vasomotor function of the vessels was studied in response 
to cumulative doses (consecutive administration of an increasing 
dose of substance every 5 min without washing out the previous 
one) of PACAP1-38 and PACAP1-27 (from 10 –9 to 10 –6  M ), which 
were synthesized as previously described  [21] , and of VIP (from 
10 –9 to 10 –6  M ; Bachem, Bubendorf, Switzerland). Peptides are 
added to the chamber containing 5 mL of Krebs solution, resulting 
in a 10 –9 to 10 –6  M final concentration. All drugs were dissolved in 
distilled water. When only the solvent (distilled water) was applied, 
there was no change in isometric force.
 Calculations  
 Maximal contractions to 60 m M KCl were calculated as per-
centage changes of the average contraction force of the 2-month-
old WT group in response to 60 m M KCl ( Fig. 1 ). Relaxation re-
sponses to peptides were calculated for each vessel individually as 
percentage changes of their own force in response to the maximal 
contraction to 60 m M KCl, which represented a baseline ( Fig. 2 ). 
 Statistical Analysis 
 All data collected as time series were compared across geno-
types, age, and dose points by 3-way ANOVA (post hoc, Holm-
Sidak). Analyses were performed using Sigma Plot 12.5 (Systat, 
Chicago, IL, USA). Differences were considered significant with 
 p values <0.05. The data are given as the mean ± standard error of 
the mean (SEM).
 Results 
 KCl-Induced Constrictions of Carotid Arteries 
 In the arteries of young mice, contraction elicited by 
60 m M KCl was significantly greater in PACAP-KO than 
in WT mice, whereas this difference diminished between 
the arteries of aging WT and PACAP-KO mice. While the 
KCl-induced vasomotor response was greater in the ar-
teries of aging WT mice than in young mice, the vasomo-
tor response was reduced in aging PACAP-KO mice 
compared to that of young ones ( Fig. 1 ).
 Effect of Cumulative Doses of PACAP1-38 on the 
Relaxation of Carotid Arteries Isolated from Young 
and Aging Mice 
 First, we obtained the responses of arteries to PA-
CAP1-38 in young (2 months old) and aging (15 months 
old) WT and PACAP-KO mice ( Fig. 2 a). In the arteries 
of young WT mice, PACAP1-38 elicited a significant 
dose-dependent relaxation (10 –8 to 10 –6  M ), whereas in 
the arteries of aging WT mice, relaxation to PACAP1-38 
was observed only at the highest dose (10 –6  M ) and it 
was significantly reduced compared to young WT mice at 
10 –8 to 10 –6  M ( Fig. 2 a, left panel). In the arteries of young 
PACAP-KO mice, PACAP1-38 induced relaxation only 
at the highest dose (10 –6  M ). In contrast, in the arteries of 
aging PACAP-KO mice, PACAP1-38-induced relaxation 
(10 –7 to 10 –6  M ) was significantly improved as compared 
to the arteries of young PACAP-KO mice at 10 –7 to 
10 –6  M ( Fig. 2 a, right panel). While arterial relaxation to 
PACAP1-38 was reduced in young PACAP-KO mice 
compared to WT mice (at 10 –8 to 10 –6  M ), aging led to 
radical changes in arterial response by diminishing these 
differences.
 Effect of Cumulative Doses of PACAP1-27 on the 
Relaxation of Carotid Arteries Isolated from Young 
and Aging Mice 
 The administration of PACAP1-27 resulted in signifi-
cant dose-dependent relaxation (10 –7 to 10 –6  M vs. base-
line) of arteries isolated from both young and aging WT 
mice. However, relaxations of arteries from aging WT 
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 Fig. 1. KCl (60 m M )-induced contractions of isolated carotid arter-
ies of young (2 months old) and aging (15 months old) WT and 
PACAP-KO mice. Arterial contractions are expressed as the per-
cent increase in tone. Data are expressed as means ± SEM ( n = 3–6/
group).  *   p < 0.05 versus 2-month-old WT mice,  +  p < 0.05 versus 
2-month-old KO mice. 
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mice were significantly reduced compared to those from 
young WT mice (only at 10 –6  M ;  Fig. 2 b, left panel). In the 
arteries of both young and aging PACAP-KO mice, PA-
CAP1-27 elicited relaxation as compared to baseline 
(young: 10 –7 to 10 –6  M ; aging: 10 –8 to 10 –6  M ). Relaxations 
of arteries to PACAP1-27 were significantly reduced in 
aging PACAP-KO mice compared to those of young PA-
CAP-KO mice (at 10 –7 to 10 –6  M ;  Fig.  2 b, right panel). 
However, while relaxation to PACAP1-27 was augment-
ed in arteries from young PACAP-KO mice compared to 
young WT mice (at 10 –7 to 10 –6  M ), there was no signifi-
cant difference in the arterial relaxations between aging 
WT and PACAP-KO mice.
 Effect of Cumulative Doses of VIP on the Relaxation of 
Carotid Arteries Isolated from Young and Aging Mice 
 Administration of VIP resulted in a relaxation of the 
arteries of both young and aging WT mice. The observed 
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 Fig. 2. Effect of cumulative dose-depen-
dent administration of PACAP1-38 ( a ), 
PACAP1-27 ( b ), and VIP ( c ) on vasomotor 
response in 2-month- and 15-month-old 
carotid arteries of WT (left panel) and PA-
CAP-KO (right panel) mice. Arterial relax-
ations are expressed as the percent decrease 
in tone (as compared to maximal tone in-
duced by 60 m M KCl). Data are expressed 
as means ± SEM ( n = 3–6/group).  *   p < 0.05 
in 15-month-old versus 2-month-old mice, 
°  p < 0.05 versus baseline in 2-month-old 
mice,  #   p < 0.05 versus baseline in 15-month-
old mice,  +  p < 0.05 in 2-month-old KO 
mice versus 2-month-old WT mice. 
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relaxation was significant at 10 –7 to 10 –6  M (for both young 
and aging mice), but there was no significance between 
them ( Fig. 2 c, left panel). In the PACAP-KO mice, VIP 
elicited a significant relaxation in the arteries of young (at 
10 –7 to 10 –6  M ) and aging (at 10 –8 to 10 –6  M ) mice, yet re-
laxation in aging PACAP-KO mice was significantly re-
duced compared to young PACAP-KO at 10 –7 to 10 –6  M 
( Fig. 2 c, right panel). However, while relaxation to VIP 
was augmented in arteries from young PACAP-KO mice 
compared to young WT mice (at 10 –7 to 10 –6  M ), there was 
no significant difference in the arterial relaxations be-
tween aging WT and PACAP-KO mice.
 In young WT mice, the greatest relaxation was ob-
served in the presence of PACAP1-38. However, in young 
PACAP-KO mice, PACAP1-27 and VIP responses were 
augmented whereas PACAP1-38 virtually did not induce 
arterial relaxation.
 Discussion 
 In this study we showed that PACAP1-38 elicited sig-
nificantly greater relaxations in the arteries of young WT 
mice than PACAP1-27 and VIP. In contrast, PACAP1-38 
did not induce relaxation in the arteries of young PA-
CAP-KO mice (except at the highest dose), whereas PA-
CAP1-27- and VIP-induced relaxations were significant-
ly augmented compared to the vasomotor responses of 
young WT mice. These results are in accordance with our 
earlier findings  [7] .
 The novel findings are: (1) KCl-induced arterial con-
striction is augmented in aging WT and reduced in PA-
CAP-KO mice compared to young mice, but there was no 
difference between the constrictions of arteries from ag-
ing WT and PACAP-KO mice; (2) PACAP peptides elic-
ited reduced relaxation in aging WT compared to young 
WT mice, whereas relaxation to VIP was unaltered, and 
(3) PACAP1-27 and VIP elicited reduced relaxation of 
arteries from aging PACAP-KO mice, whereas PA-
CAP1-38 induced significantly greater relaxation com-
pared to young PACAP-KO mice.
 KCl-Induced Tone of Arteries of Young and Aging 
Mice 
 KCl is used to test the contractile abilities of arteries 
without receptor mediation, which can be influenced by 
aging as we have previously shown  [20] . In aging WT 
mice, we observed increased contractile force develop-
ment, which is in accordance with previous findings  [11, 
20] . Increased arterial contractility in young PACAP-KO 
mice corresponds to our previous findings  [7] . On the 
contrary, in aging PACAP-KO mice, there is a decrease, 
or rather restoration (normalization) of vasomotor relax-
ation to the level which corresponds to carotid arteries of 
aging WT mice. One explanation for this phenomenon 
could be the fact that VIP-induced relaxation is main-
tained during aging. VIP is similar to PACAP, especially 
PACAP1-27, in structure and function  [1, 2] . Therefore, 
VIP may stimulate the same second level signaling related 
to PACAP, thus it can counterbalance the increased con-
tractility. These findings could have physiological impor-
tance as VIP can provide a counterbalancing mechanism 
preserving vasodilation in PACAP-deficiency or PA-
CAP-insufficiency, which can be present in pathological 
conditions  [14] and aging  [16] .
 PACAP- and VIP-Induced Vasomotor Responses of 
Carotid Arteries with Aging 
 PACAP has multifunctional regulatory roles both lo-
cally in various organs and systemically, by exerting gen-
eral effects on tissues, such the vasculature, where both 
PACAP and VIP are potent vasodilators  [1, 4, 5, 22] . In 
the present study, we found that PACAP and VIP elicited 
arterial relaxations in young male WT and PACAP-KO 
mice, similarly to our earlier report  [7] . In young WT 
mice, relaxation induced by PACAP1-38 was greater than 
that by PACAP1-27 and VIP. These observations are in 
accordance with some reports  [23, 24] , whereas other 
studies indicate higher efficacy of either PACAP1-27 or 
VIP  [6, 23] . The vasculature of humans and rats contains 
PACAP, VIP, and their receptors, and their distribution 
can differ from organ to organ  [1, 10, 13, 25] . However, it 
seems that there is no general rule concerning the poten-
cy of PACAP peptides and VIP in the vasculature. Previ-
ous studies showed vasodilatory effects of PACAP and 
VIP in different vessels of different regions, such as the 
brain  [7–10, 23, 25] , abdominal cavity  [23] , lung  [23, 24] , 
and limbs  [7] of various species.
 In young PACAP-KO mice, relaxation of the carotid 
artery to PACAP1-38 was detectable only at the highest 
concentration (10 –6  M ). In contrast, substantially and sig-
nificantly increased relaxations were observed after ad-
ministrations of PACAP1-27 and VIP. These findings are 
in accordance with our earlier report  [7] . As we reported, 
the reason for such vascular behavior could be a “bio-
logical switch” from the PACAP to VIP system, due 
to the overlapping receptorial mechanism and structural 
similarity between the PACAP1-27 and VIP  [1] . Other 
reports show that the lack of PACAP results in cardiovas-
cular defects, such as reduced cardiac function and dilata-
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tor ability, increased fibrosis, and myocardial degenera-
tive changes  [8, 14] .
 PACAP and VIP are highly conserved through evolu-
tion  [1] , indicating the importance of PACAP in a large 
array of physiological and pathophysiological processes 
 [1, 26] . During prenatal development and shortly after 
birth, there is a rapid increase in the mRNA and protein 
levels of PACAP and its receptors  [1, 26] . In contrast, 
these levels decrease with aging. Tripathy et al.  [16] re-
ported that the cerebrovascular level of PACAP is higher 
in young rats and lower in old rats. An interesting obser-
vation has been made regarding PACAP and VIP recep-
tors in the brain of old rats showing increased PAC1R, 
decreased VPAC1R, and unchanged VPAC2R levels  [26, 
27] . Several research groups have already attempted to 
identify possible compensatory mechanisms in PACAP 
deficiency. Ogawa et al.  [28] reported that serotonin or 
tyrosine hydroxylase expression did not alter in PACAP-
KO mice. As the most logical possible compensation is 
VIP, given the structural and receptorial overlapping 
with PACAP, an earlier study by Girard et al.  [29] inves-
tigated the postnatal expression of PACAP and VIP in 
knockout animals. Surprisingly, they found no postnatal 
developmental compensation by VIP in PACAP-KO an-
imals, or vice versa, of PACAP in VIP-KO mice. In PA-
CAP-KO mice, no increase of VIP expression in the 
early postnatal brain could be observed. Although these 
results still leave the question open regarding what com-
pensatory mechanisms exist in the lack of PACAP, our 
results show that VIP is involved in the compensation of 
the vasomotor functions, even if expressional alterations 
cannot be found in the postnatal brain. Differences in 
age, strain, and organ-specific mechanisms can also ex-
plain the discrepancy between our findings and those of 
Girard et al.  [29] . Another study suggested that the com-
pensatory mechanisms may be very complex, and not 
due to one molecule, as rearing PACAP-KO mice in an 
enriched environment could increase the protein levels 
of the NMDA receptor NR2B subunit, phospho-ERK, 
phospho-CaMKII, and brain-derived neurotrophic fac-
tor, resulting in the amelioration of memory impair-
ments shown in the PACAP-KO mice  [30] . The vascular 
relaxation to PACAP1-38 is reduced with aging, which is 
similar to our previous observations in old rats  [11] . An 
age-related decrease in PACAP mRNA and protein lev-
els  [16, 31] can alter PACAP-induced relaxation. Ac-
cordingly, in the old rat brain, Lee et al.  [26] reported 
increased PAC1R and unchanged VPAC2R levels with 
aging, which implies the adaptation of the PACAP sys-
tem for either compensation (in the form of receptor 
overexpression) or switch to “alternative” PACAP-medi-
ated responses (most likely VIP). The responses of arter-
ies of aging PACAP-KO mice correspond with those of 
aging WT mice, suggesting that the signal transduction 
pathway is able to adapt as age progresses. These obser-
vations clearly demonstrate that the VIP-mediated vaso-
motor effects provide an “alternative mechanism” when 
PACAP is absent (in young PACAP-KO mice;  Fig. 3 ) or 
the PACAP level is insufficient (in aging WT mice; 
 Fig. 4 ), allowing the proper vascular response to be main-
tained. Normal vascular responses are most likely 
achieved through receptor adaptation, as demonstrated 
already in young PACAP-KO mice  [7] . It is unclear why 
carotid arteries of aging PACAP-KO mice improve PA-
CAP1-38-induced relaxation, but we propose that in-
creased receptor binding serves as a compensatory mech-
anism, especially if there is an increase in levels of PAC1R, 
as previously observed by Lee et al.  [26] . In addition, age-
related vascular impairments and dysfunction  [32] could 
also influence the magnitude of the vasomotor response 
to PACAP and VIP. The translational value of our stud-
Fig. 3. Schematic illustration of vasomotor signaling of PACAP 
and VIP of carotid arteries of young (upper section) and aging 
(lower section) WT mice. Based on our previous work  [7] , we ob-
served relaxation to all 3 peptides in young WT mice. In aging WT 
mice, relaxation was reduced to PACAP1-38 and PACAP1-27, but 
not to VIP, which does not change relaxation. +/–/o, relaxation 
present/reduced/unchanged; P38, PACAP1-38; P27, PACAP1-27. 
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ies awaits further investigation, as presently available 
data show that the vasodilator effects of PACAP depend 
on the pathological conditions and are different in differ-
ent organs. For example, PACAP seems to play a major 
role in the vasodilation of meningeal arteries in migraine 
patients  [33] and general blood flow changes upon intra-
venous administration  [34] , while its physiological role 
in cavernous blood vessels is questioned due to the mark-
edly stronger effect of VIP  [35] .
 The physiological role of PACAP in aging is empha-
sized, among others, by links between PACAP and neu-
rodegenerative diseases. Age-related neurodegenerative 
diseases are associated with reduced levels of PACAP, 
and symptoms of Parkinson’s disease can be attenuated 
by the administration of exogenous PACAP  [18] . PA-
CAP-KO mice exhibit early aging symptoms, including 
early retinal aging signs  [36] , impairment of memory, and 
learning ability  [17] , which has been shown to be amelio-
rated by enriched environment  [30] or reversed with PA-
CAP treatment  [31] .
 Conclusions 
 This is the first study aiming to characterize the effects 
of aging on the relaxant function of isolated carotid arter-
ies in normal conditions and in PACAP deficiency by 
utilizing exogenous PACAP1-38, PACAP1-27, and VIP 
neuropeptides. We found that both PACAP deficiency 
and aging shift the response from PACAP-38 to the VIP 
system, which seems to be preserved in aging. These 
ideas are depicted in  Figures 3 and  4 showing that the 
VIP system may be an alternative/backup pathway that 
maintains the vasomotor function of arteries in aging-
induced PACAP deficiency/insufficiency, underlying 
the physiological importance of both the PACAP and 
VIP pathways in the regulation of the vasomotor func-
tion of arteries and perhaps coupling it to neural func-
tions.
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 Fig. 4. Schematic illustration of vasomotor signaling of PACAP 
and VIP of carotid arteries of young (upper section) and aging 
(lower section) KO mice. On the basis of our previous work  [7] , in 
young KO mice we observed a loss of relaxation to PACAP1-38 
peptide, but improved relaxation to PACAP1-27 and VIP as com-
pared to young WT mice. In aging KO mice, increased relaxation 
was observed to PACAP1-38, but relaxation was reduced to PA-
CAP1-27 and VIP compared to young KO mice (upper section). 
Magnitude of achieved relaxations to all peptides in aging KO mice 
correspond to aging WT mice (Fig.  3, lower section). +/–, in-
creased/reduced relaxation; P38, PACAP1-38; P27, PACAP1-27. 
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